Effects of 6-chloro-2',3'-dideoxyguanosine (6-Cl-ddG) in surface lymph nodes of rhesus monkeys (Macaca mulatta) chronically infected with simian immunodeficiency virus (SIVmac239).
We studied the effects of 6-chloro-2',3'-dideoxyguanosine (6-Cl-ddG), an antiretroviral drug, in surface lymph nodes of rhesus monkeys (Macaca mulatta) chronically infected with simian immunodeficiency virus (SIV). The rhesus monkeys were treated with 25 mg/kg of 6-Cl-ddG every 8 hr for 2 weeks. We performed sequential biopsies of the surface lymph nodes three times: before, during, and after the drug treatment. The 6-Cl-ddG dramatically decreased the number of infectious virus (measured by limiting dilution assay) in lymph node mononuclear cells. This decrease was consistent with the decrease in the number of viral RNA-positive cells in lymph nodes (analyzed by in situ hybridization). Histopathological analysis revealed that hyperplastic lymphoid follicles were reduced in size, especially, enlarged areas of centroblasts in lymphoid follicles (the so-called dark areas of germinal centers) were declined. Our results demonstrated that 6-Cl-ddG decreased the viral burden concomitantly with reduced hyper-activation of germinal centers in lymphoid follicles of SIV-infected rhesus monkeys.
Otani
I
I
Tsukuba Primate Center, National Institute of Infectious Diseases, Ibaraki, Japan.
Fujii
Y
Y
Akari
H
H
Mukai
R
R
Mori
K
K
Ono
F
F
Kojima
E
E
Machida
M
M
Murakami
K
K
Doi
K
K
Yoshikawa
Y
Y
D000818:Animals; D015703:Antigens, CD / Q000032:analysis; D018951:Antigens, CD20 / Q000032:analysis; D015214:Antigens, Differentiation, Myelomonocytic / Q000032:analysis; D000998:Antiviral Agents / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D017252:CD3 Complex / Q000032:analysis; D015224:Dideoxynucleosides / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D006684:HLA-DR Antigens / Q000032:analysis; D007150:Immunohistochemistry; D017403:In Situ Hybridization / Q000662:veterinary; D007279:Injections, Subcutaneous / Q000379:methods / Q000662:veterinary; D019394:Ki-67 Antigen / Q000032:analysis; D007963:Leukocytes, Mononuclear / Q000187:drug effects / Q000821:virology; D008198:Lymph Nodes / Q000187:drug effects / Q000473:pathology / Q000821:virology*; D008253:Macaca mulatta; D012367:RNA, Viral / Q000032:analysis / Q000235:genetics; D016097:Simian Acquired Immunodeficiency Syndrome / Q000188:drug therapy* / Q000473:pathology / Q000821:virology; D015302:Simian Immunodeficiency Virus / Q000187:drug effects* / Q000235:genetics / Q000276:immunology; D000097382:CD68 Molecule
D015703:Antigens, CD; D018951:Antigens, CD20; D015214:Antigens, Differentiation, Myelomonocytic; D000998:Antiviral Agents; D017252:CD3 Complex; D015224:Dideoxynucleosides; D006684:HLA-DR Antigens; D019394:Ki-67 Antigen; D012367:RNA, Viral; C095793:6-chloro-2',3'-dideoxyguanosine; C067980:CD68 antigen, human; D000097382:CD68 Molecule